Aflibercept vs placebo and FOLFIRI for MCRC

Bookmark and Share
Published: 4 Oct 2011
Views: 5733
Rating:
Save
Prof Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Prof Josep Tabernero, Vall d'Hebron Institute of Oncology, Barcelona, Spain, talks to ecancer Managing Editor Prof Gordon McVie about research he presented at the 2011 European Multidisciplinary Cancer Conference, Stockholm. Results From VELOUR, a Phase III Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients with Previously Treated Metastatic Colorectal Cancer (MCRC). FOL – folinic acid (leucovorin), F – fluorouracil (5-FU) and IRI – irinotecan.